Welcome to our dedicated page for Microport Cardio news (Ticker: MCRCY), a resource for investors and traders seeking the latest updates and insights on Microport Cardio stock.
MicroPort® CardioFlow Medtech Corporation (CardioFlow) (Stock Code: 02160.HK) is a leading innovative medical device company specializing in structural heart devices. Recently, CardioFlow announced the EU CE-MDR certification for its second-generation transcatheter aortic valve implantation (TAVI) device, VitaFlow LibertyTM. This electric retrievable transcatheter aortic valve system offers minimal trauma, quick recovery, and enhanced quality of life for patients with aortic heart valve disease. With a diverse product pipeline covering transcatheter aortic, mitral, and tricuspid valves, CardioFlow is dedicated to advancing heart valve interventions and benefiting patients globally.
MicroPort CardioFlow Medtech (Stock Code: 02160.HK) has announced that its VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System has received EU CE-MDR certification. This milestone highlights the device as a cutting-edge solution for aortic valve stenosis and regurgitation, conditions affecting over 47 million people globally. VitaFlow Liberty™ boasts minimal trauma, quick recovery, and enhanced quality of life, aiming to replace open-heart surgery.
The certification is expected to accelerate global clinical adoption, with the device already covering 700 core hospitals in 10 countries, treating over 10,000 patients. Clinical data presented at PCR London Valves 2023 showed promising long-term outcomes. Pre-market clinical trials in Europe also received positive feedback. This achievement is part of CardioFlow's broader strategy to diversify revenue and strengthen competitive positioning.
4C Medical Technologies has successfully completed a $35.4 million Series C Preferred Stock financing, led by MicroPort CardioFlow Medtech Corporation. Alongside this funding, Saravana Kumar, PhD, has been appointed as the President & CEO, transitioning from interim leadership since March 2021. The funds are intended to enhance the AltaValve transcatheter mitral valve replacement device and initiate a tricuspid program, expanding treatment options for patients. The funding underscores the company's commitment to addressing mitral regurgitation and supporting future innovations.
FAQ
What is CardioFlow known for?
What does VitaFlow LibertyTM offer to patients?
Where is CardioFlow headquartered?
What recent milestone did CardioFlow achieve?
What makes VitaFlow LibertyTM unique?
